NEW YORK (GenomeWeb) – Twist Bioscience has signed a deal to offer its customers therapeutic antibody design and optimization services using software developed by Distributed Bio, the companies announced today.
Under the terms of the arrangement, Distributed Bio will develop custom antibody design software that is optimized for use with Twist's high-throughput long oligo synthesis technology and will allow Twist's biopharmaceutical customers to access its proprietary G-protein coupled receptor (GPCR) target library. The software will be integrated into Twist's e-commerce platform, which is expected to launch next year.
Additional terms of the deal were not disclosed.
"By integrating antibody design and screening with the GPCR-targeting antibody library, our other specialized library offerings, and the ability to generate the synthetic DNA rapidly, we look forward to partnering with pharmaceutical and biotechnology companies to accelerate the research cycle, mitigate the downside risk of early discovery, and improve the patentability of antibody therapeutics," Twist CEO Emily Leproust said in a statement.